In Brief: Pfizer earnings, NAD decision, DXM bill, FDA warning, regulatory agenda
This article was originally published in The Tan Sheet
Pfizer’s OTC pain sales drop; NAD Procera AVH claims to FTC; House introduces DXM bill; FDA warns medical food firm; Regulatory Agenda pushes back OTC actions; meetings address terrorism-related food adulteration; and more news In Brief.
You may also be interested in...
The Consumer Healthcare Products Association’s No. 1 legislative priority in 2014 is restoring OTC coverage by flexible spending and health savings accounts, followed by a “close No. 2” goal of establishing an age requirement to buy DXM products. Other goals include protecting access to PSE products and blocking take-back programs.
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.